287 POSTER Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity
2008
Ala213 Leu83 Glu211 Glu81 Gln85 The optimisation of fragments to low nanomolar inhibitors can be achieved with a limited number of compounds, particularly if good structural data are available.3 In this work X-ray crystallographic structures were generated using a novel soakable form of Aurora A. Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive targets for the treatment of cancer.4 In addition to Aurora A and Aurora B, AT9283 was also found to inhibit a number of other kinases including JAK2 and imatinib-resistant Abl (T315I). AT9283 demonstrated in vivo efficacy in mouse xenograft models and is currently under evaluation in Phase I/II clinical trials.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
7
References
3
Citations
NaN
KQI